The Costs of Hepatitis C by Liver Disease Stage: Estimates from the Veterans Health Administration

Risha Gidwani-Marszowski (), Douglas K. Owens, Jeanie Lo, Jeremy D. Goldhaber-Fiebert, Steven M. Asch and Paul G. Barnett
Additional contact information
Risha Gidwani-Marszowski: VA Health Economics Resource Center, VA Palo Alto Health Care System
Douglas K. Owens: VA Center for Innovation to Implementation, VA Palo Alto Health Care System
Jeanie Lo: VA Health Economics Resource Center, VA Palo Alto Health Care System
Jeremy D. Goldhaber-Fiebert: Stanford University
Steven M. Asch: VA Center for Innovation to Implementation, VA Palo Alto Health Care System
Paul G. Barnett: VA Health Economics Resource Center, VA Palo Alto Health Care System

Applied Health Economics and Health Policy, 2019, vol. 17, issue 4, No 7, 513-521

Abstract: Abstract Background The release of highly effective but costly medications for the treatment of hepatitis C virus combined with a doubling in the incidence of hepatitis C virus have posed substantial financial challenges for many healthcare systems. We provide estimates of the cost of treating patients with hepatitis C virus that can inform the triage of pharmaceutical care in systems with limited healthcare resources. Methods We conducted an observational study using a national US cohort of 206,090 veterans with laboratory-identified hepatitis C virus followed from Fiscal Year 2010 to 2014. We estimated the cost of: non-advanced Fibrosis-4; advanced Fibrosis-4; hepatocellular carcinoma; liver transplant; and post-liver transplant. The former two stages were ascertained using laboratory result data; the latter stages were ascertained using administrative data. Costs were obtained from the Veterans Health Administration’s activity-based cost accounting system and more closely represent the actual costs of providing care, an improvement on the charge data that generally characterizes the hepatitis C virus cost literature. Generalized estimating equations were used to estimate and predict costs per liver disease stage. Missing data were multiply imputed. Results Annual costs of care increased as patients progressed from non-advanced Fibrosis-4 to advanced Fibrosis-4, hepatocellular carcinoma, and liver transplant (all p

Date: 2019
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s40258-019-00468-5 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:aphecp:v:17:y:2019:i:4:d:10.1007_s40258-019-00468-5

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40258

DOI: 10.1007/s40258-019-00468-5

Access Statistics for this article

Applied Health Economics and Health Policy is currently edited by Timothy Wrightson

More articles in Applied Health Economics and Health Policy from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().